In this phase I first-in-human study, which is the first to report clinical data on PPARα modulation in solid tumors, we tested the hypothesis that inhibiting PPARα with TPST-1120 would be tolerable in patients with advanced cancer and would have anticancer activity. Here, PPARA is linked to cancer.